Das Bergbauunternehmen ist seit August 2015 nicht mehr an einer Börse gelistet. Das Delisting von Mindesta Inc. fand aufgrund einer Umstrukturierung statt.
Ältere Artikel von und über die Gesellschaft befinden sich im Archiv.
Mindesta Inc. meldete gestern, dass die Regulierungsbehörde U.S. Financial Industry Regulatory Authority noch keinen Ex-Dividende-Tag für die Ausgabe der Stammaktien von Northern Graphite Corporation, die sich in Besitz von Mindesta befinden, festgelegt hat, da die Überprüfung noch nicht abgeschlossen wurde. Aktionäre, die ihre Mindesta-Stammaktien [...]
Mindesta ist ein Explorationsunternehmen, dem noch 26,2% der ausstehenden Aktien von Northern Graphite Corporation gehören. Mindesta wird diese Aktien im Verhältnis 1:1 an seine Aktionäre als Aktiendividende ausgeben. Wer am 5. Januar 2012 Aktionär von Mindesta ist, wird am 25.Januar 2012 die gleiche Anzahl Northern Graphite eingebucht bekommen [...]
Mindesta is pleased to announce the collaboration between CTT Pharmaceutical Holdings Inc and Phytoplant Research, S.L.. Phytoplant Resesarch S.L. will provide CTT Pharmaceuticals Inc., novel unique extracts from their proprietary Cannabis varieties to manufacture novel quick dissolving oral wafers that offer the entourage therapeutic effects of [...]
Mindesta Inc. CTT Pharmaceuticals Inc. has issued an update from its president to shareholders. The update is as follows: To CTT Shareholders: Let me first take this opportunity to thank you for your continued interest in CTT Pharmaceuticals. Our gains have been a direct result of the continued support of shareholders like you. At this time, I [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Dr. Stephen Houldsworth to it's advisory board of CTT Pharmaceuticals effective immediately: "I am pleased to be working with CTT in an advisory role as they work to create evidence based medicines within the Cannabis arena using their novel drug delivery systems. At a [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Michelle Hamilton-Page, Digital Strategist, to the advisory board of CTT Pharmaceuticals effective immediately. "We value the addition of Ms. Hamilton-Page, as our holistic approach includes creating better adherence and safety for our future opioid based pain management [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Michelle Hamilton-Page, Digital Strategist, to the advisory board of CTT Pharmaceuticals effective immediately. "We value the addition of Ms. Hamilton-Page, as our holistic approach includes creating better adherence and safety for our future opioid based pain management [...]
